<DOC>
	<DOCNO>NCT00248287</DOCNO>
	<brief_summary>The purpose study determine objective response rate produce irinotecan carboplatin therapy without Erbitux patient Metastatic Breast Cancer .</brief_summary>
	<brief_title>PhII ICb With/Without Erbitux MBC Pts</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>INCLUSION CRITERIA : Male female patient eligible inclusion study meet follow criterion : Has cytologically pathologically confirm , breast cancer document HER2+ ( positive ) ( 3+ IHC FISH+ ) HER2 ( negative ) disease . ER , PR , HER2 status must document electronic Case Report Form ( eCRF ) NOTE : Patients whose breast cancer HER2 ( 2+ ) IHC must undergo FISH test confirm HER2+ ( positive ) status . Has clinically confirm Stage IV metastatic breast cancer ( MBC ) Has undergone prior Herceptin therapy breast cancer HER2+ ( positive ) Has measurable MBC define Response Evaluation Criteria Solid Tumors ( RECIST ) Criteria NOTE : Ascites , pleural effusion , bone metastasis consider measurable . Has 1 prior chemotherapy regimens metastatic disease . Previously untreated disease permit . Has prior treatment irinotecan , carboplatin , cisplatin Has ECOG Performance Status ( PS ) 02 Is great 18 year age Please see protocol specific detail regard appropriate laboratory value inclusion study . Any prior radiation therapy complete &gt; 2 week prior start study treatment NOTE : Previously irradiate lesion evaluable ; however , patient still eligible . Patients must least 1 measurable lesion baseline . Has negative serum pregnancy test within 7 day prior registration ( female patient childbearing potential ) . A pregnancy test also require within 7 day Dose 1 . If fertile , patient ( male female ) agree use acceptable method birth control avoid pregnancy duration study period 6 month thereafter . Has sign Patient Informed Consent Form Has sign Patient Authorization Form ( HIPAA ) Has paraffinembedded breast cancer tissue ( either paraffin block 20 unstained slide ) available analysis EGFR , cytokeratin , biological marker . These sample send Molecular Profiling Institute ( MPI ; see Appendix VII ) . NOTE : Availability sample confirm prior randomization ( late , prior first dose ) . EXCLUSION CRITERIA : Has Stage IIII breast cancer nonmeasurable metastatic breast cancer , disease describe inclusion criterion # 1 Has receive prior treatment irinotecan , carboplatin , cisplatin Is receive concurrent chemotherapy indicate study protocol investigational agent ( ) Has receive prior therapy specifically directly target EGFR pathway . Prior Herceptin require HER2+ patient . Has prior severe infusion reaction monoclonal antibody Has receive organ allograft ( ) corneal , bone , skin Has clinically significant uncontrolled cardiac disease ( eg , congestive heart failure , symptomatic coronary artery disease cardiac arrhythmia wellcontrolled medication ) myocardial infarction &lt; 12 month Has ongoing peripheral neuropathy &gt; Grade I Has evidence symptomatic untreated central nervous system ( CNS ) metastases ( unless CNS metastasis irradiate ) . Chronic steroid treatment treatment CNS metastases must discontinue great 4 week prior study enrollment . Has significant comorbidity , opinion clinical investigator , might compromise aspect study Has active uncontrolled infection Has acute hepatitis know HIV positive Has history malignancy within last 5 year could affect diagnosis assessment MBC , exception carcinoma cervix situ , carcinoma bladder situ , basal cell carcinoma Has previously complete chemotherapy regimen within 3 week prior start study treatment , related toxicity unresolved prior start study treatment NOTE : If patient receive prior weekly daily chemotherapy , he/she may begin study therapy 2 week stop prior therapy provide toxicity resolve ; peripheral neuropathy must less Grade I per exclusion criterion # 8 . Has major surgery within 3 week start study treatment , without complete recovery Has participate investigational drug study within 4 week precede start study treatment Has receive concurrent immunotherapy hormonal anticancer agent within 2 week prior start study treatment Is receive tyrosine kinase inhibitor ( ie , IressaTM ) Has prior stem cell bone marrow transplant prior hematologic malignancy Is pregnant lactating Is unable comply requirement study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>